Spironolactone Tablet, Film Coated
Product Images NDC 55154-5517

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Spironolactone (NDC 55154-5517). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Cardinal Health 107, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

9572e6f6 B46c 44a0 8027 5942b02d2f86 00

Spironolactone tablets, USP 25 mg, film-coated oral tablets packaged in a unit dose container with 10 tablets. The label shows the NDC 55154-5517 and includes storage instructions to keep at 20° to 25°C (68° to 77°F) and protection from light. It states the product is RX only and intended for institutional use. Manufactured by Mylan Pharmaceuticals Inc. and distributed by Cardinal Health 107, LLC.*

FDA Label Image

Bag Label (Image 01)

Chemical structure of spironolactone depicted as a skeletal formula showing carbon rings, methyl groups, and functional groups consistent with its steroidal lactone structure.*

FDA Label Image

Bag Label (Image 02)

A Kaplan-Meier survival probability curve comparing Spironolactone and placebo groups over 48 months. The y-axis represents probability from 0 to 1, and the x-axis shows time in months. Two curves display outcomes for Spironolactone (n=822) and placebo (n=841), with a noted log-rank p-value of less than 0.001.*

FDA Label Image

Bag Label (Image 03)

A forest plot chart showing hazard ratios (HR) and 95% confidence intervals (CI) for various subgroups in a study comparing Spironolactone versus placebo. Subgroups include age, sex, race, LVEF, heart failure type, NYHA class, diabetes status, serum creatinine, creatinine clearance, potassium levels, digoxin use, ACE inhibitor use, and beta blocker use, with HR values plotted on a scale from 0.2 to 1.4 indicating relative benefit between Spironolactone and placebo.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.